Plaque Psoriasis (CAIN2322)

Psoriasis is an autoimmune disease that causes raised, red, scaly patches to appear on the skin.
It typically affects the outside of the elbows, knees or scalp, though it can appear on any location. Some people report that psoriasis is itchy, burns and stings. Psoriasis can be associated with rheumatoid arthritis, Crohn’s disease, and osteoporosis. When untreated, it can lead to other serious health conditions, such as diabetes, heart disease and depression.

The purpose of this study is to determine whether early intervention with subcutaneous secukinumab 300 mg (an injection) in patients with new-onset moderate to severe plaque psoriasis may lead to prolonged symptom free periods by preventing reactivation of old lesions or ultimately totally hindering the occurrence of new lesions, i.e., changing the natural course of the disease.

https://clinicaltrials.gov/ct2/show/NCT03020199?term=CAIN+2322&rank=1

Register Today!

Let others know about this Trial!

Trial Information

Start Date27 March 2017
End Date19 April 2022
Trial Duration4 Years
Number of Visits21
Lead CRCSuzanne Fleming
StatusIn Recruitment

For additional information on this trial contact:

Phone705-566-0005